The phase 2 trial aims to establish whether the antitumor effect of nivolumab can be enhanced by concurrent administration of stereotactic body radiotherapy in people with metastatic renal cell carcinoma who have received two or fewer antiangiogenic therapies.
Initial results will be presented at ASCO GU 2020:
Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study
Cristina Masini, AUSL-IRCCS Reggio Emilia, Italy
Saturday, 15 February: 7:55–9:30 AM (Abstract 613)